Pyxis Oncology Inc - Asset Resilience Ratio
Pyxis Oncology Inc (PYXS) has an Asset Resilience Ratio of 63.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pyxis Oncology Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Pyxis Oncology Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PYXS current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Pyxis Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Pyxis Oncology Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.34 Million | 63.76% |
| Total Liquid Assets | $67.34 Million | 63.76% |
Asset Resilience Insights
- Very High Liquidity: Pyxis Oncology Inc maintains exceptional liquid asset reserves at 63.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pyxis Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Pyxis Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Pyxis Oncology Inc (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Pyxis Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 68.37% | $107.46 Million | $157.18 Million | +5.26pp |
| 2023-12-31 | 63.11% | $109.63 Million | $173.73 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $211.38 Million | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more